Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

INNOCARE
诺诚健华

InnoCare Pharma Limited
諾誠健華醫藥有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9969)

VOLUNTARY ANNOUNCEMENT

NEW DRUG APPLICATION FOR ORELABRUTINIB FOR THE TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA PATIENTS ACCEPTED BY THE CENTER FOR DRUG EVALUATION OF THE CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by InnoCare Pharma Limited (the "**Company**") on a voluntary basis to inform shareholders and potential investors of the Company's latest business developments.

The Board of Directors (the "**Board**") is pleased to announce that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the new drug application (NDA) submission for orelabrutinib, a Bruton Tyrosine Kinase (BTK) inhibitor, for the treatment of patients with primary immune thrombocytopenia (ITP) in China.

ITP represents an important expansion of orelabrutinib beyond hematologic malignancies into the field of autoimmune diseases. With its high target selectivity and a favorable safety profile, orelabrutinib is well positioned to become a preferred BTK inhibitor for the treatment of ITP. As of the date of this announcement, no BTK inhibitor has been approved in China for ITP.

ITP, also referred to as immune thrombocytopenic purpura, is an acquired immune mediated disorder characterized by a decrease in peripheral blood platelet counts, resulting in an increased risk of bruising and bleeding. Global data indicate that there are over 200,000 new cases of ITP annually, with approximately 60,000 new cases occurring in China each year, representing significant unmet medical needs.

Orelabrutinib has demonstrated favorable efficacy and safety in the field of autoimmune diseases. In addition to ITP, Phase III registrational trials for orelabrutinib in systemic lupus erythematosus (SLE), primary progressive multiple sclerosis (PPMS), and secondary progressive multiple sclerosis (SPMS) are currently underway in China and globally.

Cautionary Statement as required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize orelabrutinib for the treatment of ITP successfully. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
InnoCare Pharma Limited
Dr. Jisong Cui
Chairperson and Executive Director

Hong Kong, 28 May 2026

As at the date of this announcement, the Board comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi and Mr. Ronggang Xie as non-executive Directors, and Ms. Lan Hu, Dr. Dandan Dong and Prof. Kunliang Guan as independent non-executive Directors.